To this end, we developed a therapeutic strategy to target overexpressed BCL-2 in ER+ breast cancer cells with exosomes loaded with small interfering RNA (siRNA) targeting BCL-2 (siBCL-2) derived from lentivirally modified NK cells. This evidence concerns the gene BCL2 and breast cancer.